0.0300
0.0000
(0.00%)
As of August 19 at 4:00:00 PM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Expense
142,278
142,278
105,957
80,020
32,868
Operating Income
-142,278
-142,278
-105,957
-80,020
-32,868
Net Non Operating Interest Income Expense
8,510
8,510
7,833
2,777
49
Other Income Expense
109,427
109,427
907
997
434
Pretax Income
-24,342
-24,342
-97,217
-76,246
-32,385
Net Income Common Stockholders
-24,342
-24,342
-97,217
-76,246
-32,385
Average Dilution Earnings
-43,793
-43,793
--
--
--
Diluted NI Available to Com Stockholders
-68,135
-68,135
-97,217
-76,246
-32,385
Total Operating Income as Reported
-141,446
-141,446
-105,957
-80,020
-32,868
Total Expenses
142,278
142,278
105,957
80,020
32,868
Net Income from Continuing & Discontinued Operation
-24,342
-24,342
-97,217
-76,246
-32,385
Normalized Income
-132,525
-132,525
-97,217
-76,246
-32,385
Interest Income
8,510
8,510
7,833
2,777
49
Net Interest Income
8,510
8,510
7,833
2,777
49
EBIT
-142,278
-142,278
-105,957
-80,020
-32,868
EBITDA
-141,146
-141,146
-104,427
-78,719
-32,334
Reconciled Depreciation
1,132
1,132
1,530
1,301
534
Net Income from Continuing Operation Net Minority Interest
-24,342
-24,342
-97,217
-76,246
-32,385
Total Unusual Items Excluding Goodwill
108,183
108,183
--
--
--
Total Unusual Items
108,183
108,183
--
--
--
Normalized EBITDA
-249,329
-249,329
-104,427
-78,719
-32,334
12/31/2021 - 1/8/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LIFE
ANVS Annovis Bio, Inc.
1.2801
-9.18%
AVXL Anavex Life Sciences Corp.
8.15
-1.81%
GLUE Monte Rosa Therapeutics, Inc.
3.7150
-4.50%
IKT Inhibikase Therapeutics, Inc.
1.8408
-6.79%
ABEO Abeona Therapeutics Inc.
4.4150
-10.81%
KTRA
SCPH scPharmaceuticals Inc.
2.2600
-1.74%
AXSM Axsome Therapeutics, Inc.
100.32
-7.02%
PIRS